on MEDINCELL (EPA:MEDCL)
UZEDY® Obtains Approval in South Korea Following Success in the United States
Medincell announces that UZEDY®, an extended-release risperidone injection, has been approved in South Korea. This drug, intended for the treatment of schizophrenia, will be marketed by Teva Handok, a joint venture between Teva and Handok, a key player in Korean healthcare. UZEDY® has already achieved commercial success in the United States, with net sales of $117 million in 2024 and $95 million in the first half of 2025.
Medincell benefits from royalties on global sales and is eligible for commercial milestones of $105 million. Christophe Douat, CEO of Medincell, emphasizes that this approval will strengthen the commercial momentum of UZEDY®.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all MEDINCELL news